Summary
KYNB Chart
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
Kyntra Bio (KYNB) came out with a quarterly loss of $4.68 per share versus the Zacks Consensus Estimate of a loss of $3.18. This compares to a loss of $3.38 per share a year ago.
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kyntra Bio, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $5.3 | $6.97 | $1.67 | 31.51% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 200 | $1,356 | $1,414 | $58 | 4.28% |
| NA Nizar Araji National Bank Of Canada /FI/ | 193 | $1,308.54 | $1,345.21 | $36.67 | 2.8% |
 Anthony Scaramucci SkyBridge Capital II LLC | 400,000 | $2.49M | $2.82M | $331,540 | 13.32% |
Kyntra Bio, Inc. (KYNB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kyntra Bio, Inc. ever had a stock split?
Kyntra Bio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Thane Wettig CEO | NASDAQ (NGS) Exchange | 31572Q881 CUSIP |
| US Country | 34 Employees | - Last Dividend | 17 Jun 2025 Last Split | 14 Nov 2014 IPO Date |
Overview
FibroGen, Inc. is a pioneering biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to address significant unmet medical needs. Since its establishment in 1993, the company has dedicated its efforts to advancing science and medicine in areas where they can make a substantial difference. With a head office located in San Francisco, California, FibroGen is at the forefront of biotechnological innovation, guided by collaboration agreements with global leaders like Astellas Pharma Inc. and AstraZeneca AB. This strategic positioning allows FibroGen to not only develop but also potentially deliver game-changing treatments on a worldwide scale.
Products and Services
- Pamrevlumab
A forefront innovation by FibroGen, Pamrevlumab, is a human monoclonal antibody that targets the connective tissue growth factor (CTGF). It is currently in Phase III clinical development for patients with locally advanced pancreatic cancer. By focusing on CTGF, Pamrevlumab aims to offer a novel treatment pathway for this challenging disease, potentially improving the survival and quality of life for patients facing pancreatic cancer.
- Roxadustat
This oral small molecule inhibitor marks a significant breakthrough in the treatment of anemia associated with chronic kidney disease (CKD) and myelodysplastic syndromes (MDS). By inhibiting hypoxia-inducible factor prolyl hydroxylase activity, Roxadustat addresses anemia by mimicking the body’s response to high altitudes, thus promoting red blood cell production. Successfully completing Phase III clinical development in various regions including China, Europe, and Japan, Roxadustat stands out as a critical advancement in managing CKD and MDS-related anemia.
